Metastatic Head and Neck Squamous Cell Carcinoma Clinical Trials

46 clinical trials for Metastatic Head and Neck Squamous Cell Carcinoma across international registries, including 17 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study — RECRUITING · PHASE2
• Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment — RECRUITING · PHASE3
• PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC — RECRUITING · PHASE2
• FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC — RECRUITING · PHASE2
• Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer — RECRUITING · PHASE2
• Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation — RECRUITING · NA
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program — RECRUITING · PHASE2
• Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE3
• Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC — RECRUITING · NA
• Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer — RECRUITING · PHASE1
• Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial — RECRUITING · PHASE2
• A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab — RECRUITING · PHASE1
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers — ACTIVE_NOT_RECRUITING · PHASE2
• Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck — ACTIVE_NOT_RECRUITING · PHASE3
• Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor — ACTIVE_NOT_RECRUITING · PHASE2
• Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck — ACTIVE_NOT_RECRUITING · PHASE2
• Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. — NOT_YET_RECRUITING · PHASE4
• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck — ACTIVE_NOT_RECRUITING · PHASE2
• Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial — NOT_YET_RECRUITING · PHASE2
• Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer — TERMINATED · PHASE2
• Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) — WITHDRAWN · NA
• Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition — COMPLETED · PHASE2
• Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC — COMPLETED · PHASE2
• TACTI-003 (Two ACTive Immunotherapeutics): A multicenter, open label, randomized, Phase II trial to investigate a soluble LAG-3 fusion protein, eftilagimod alpha (efti; IMP321) in combination with pembrolizumab (PD-1 antagonist) for first line treatment of subjects with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) — OTHER · PHASE2
• An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC — ACTIVE_NOT_RECRUITING · PHASE2
• Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer — COMPLETED · NA
• Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease — COMPLETED · PHASE1
• Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies — COMPLETED · PHASE1
• Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer — WITHDRAWN · NA
• INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — WITHDRAWN · PHASE2
• Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — TERMINATED · PHASE1
• Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat — TERMINATED · PHASE2
• Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin — TERMINATED · PHASE2
• A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — TERMINATED · PHASE1
• Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma — OTHER · NA

Refine this search